19.75
-0.42
(-2.08%)
At close: February 13 at 3:00:05 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,428,324.79
1,262,530.88
1,008,076.47
803,362.67
721,440.23
Cost of Revenue
601,983.86
556,557.82
487,676.48
408,644.20
380,536.55
Gross Profit
826,340.93
705,973.07
520,399.99
394,718.47
340,903.68
Operating Expense
443,252.83
409,352.01
292,047.45
202,439.46
142,133.47
Operating Income
383,088.10
296,621.06
228,352.54
192,279.01
198,770.21
Net Non Operating Interest Income Expense
17,376.90
12,880.99
2,753.58
7,100.13
4,932.35
Pretax Income
388,860.61
329,079.82
240,752.45
192,011.30
185,738.40
Tax Provision
48,725.06
40,010.31
32,473.28
23,729.94
28,511.18
Net Income Common Stockholders
340,667.68
289,419.39
210,964.63
168,713.89
157,227.22
Basic EPS
0.84
0.71
0.52
0.42
0.42
Diluted EPS
0.82
0.71
0.52
0.42
0.42
Basic Average Shares
405,716.51
407,632.94
405,701.22
401,699.74
374,350.53
Diluted Average Shares
414,659.63
407,632.94
405,701.22
401,699.74
374,350.53
Total Operating Income as Reported
391,472.51
330,727.14
241,277.18
193,620.65
187,270.47
Rent Expense Supplemental
--
--
--
--
2,711.38
Total Expenses
1,045,236.69
965,909.82
779,723.93
611,083.66
522,670.02
Net Income from Continuing & Discontinued Operation
340,667.68
289,419.39
210,964.63
168,713.89
157,227.22
Normalized Income
352,701.15
301,789.23
222,643.83
167,837.49
158,567.91
Interest Income
26,330.34
16,530.37
4,410.49
8,267.54
5,461.97
Interest Expense
7,294.12
2,744.28
1,011.73
643.75
--
Net Interest Income
17,376.90
12,880.99
2,753.58
7,100.13
4,932.35
EBIT
396,154.74
331,824.11
241,764.17
192,655.05
198,770.21
EBITDA
396,154.74
410,934.50
311,008.90
247,428.65
230,794.12
Reconciled Cost of Revenue
601,983.86
556,557.82
487,676.48
408,644.20
380,536.55
Reconciled Depreciation
--
79,110.39
69,244.72
54,773.60
32,023.91
Net Income from Continuing Operation Net Minority Interest
340,667.68
289,419.39
210,964.63
168,713.89
157,227.22
Total Unusual Items Excluding Goodwill
-13,757.28
-14,081.96
-13,500.13
999.99
-1,583.81
Total Unusual Items
-13,757.28
-14,081.96
-13,500.13
999.99
-1,583.81
Normalized EBITDA
409,912.02
425,016.45
324,509.03
246,428.66
232,377.93
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,723.82
-1,712.12
-1,820.93
123.58
-243.12
12/31/2020 - 9/21/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HQ1.MU Oruka Therapeutics Inc. R
11.20
+3.70%
6Y4.F Vicore Pharma Holding AB (publ)
0.7310
-2.14%
8F8.SG SynAct Pharma AB
1.3460
-1.68%
REGN.MX Regeneron Pharmaceuticals, Inc.
13,757.24
+0.80%
ICY.SG Incyte Corp
66.72
+1.15%
22UA.DU BioNTech SE
112.70
+4.35%
PH4.F CStone Pharmaceuticals
0.3060
-2.55%
ALGEN.PA genOway Société anonyme
3.5400
+2.31%
0WA2.IL Cellectis S.A.
1.5200
0.00%
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.3310
+0.61%